{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(9)"],"submitter":["Tian K"],"pubmed_abstract":["Numerous viral outbreaks have threatened us throughout history. Here, we demonstrated a nucleic acid-based antiviral strategy named AntiV-SGN. Unlike those CRISPR-mediated methods, AntiV-SGN has advantages of no targets' sequence limitation, such as protospacer adjacent motif (PAM) or protospacer flanking sequence (PFS), being universal for both DNA and RNA viruses. AntiV-SGN was composed of a FEN1 protein and specific hpDNAs targeting viruses' nucleic acid. Its antiviral ability was tested on SARS-CoV-2 and HBV respectively. Reporter assays in human cells first illustrated the feasibility of AntiV-SGN. Then, it was verified that AntiV-SGN destroyed about 50% of live RNAs of SARS-CoV-2 in Vero cells and 90% cccDNA of HBV in HepG2.2.15 cells. It was also able to remove viral DNA integrated "],"journal":["Microbial biotechnology"],"pagination":["2488-2501"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9437879"],"repository":["biostudies-literature"],"pubmed_title":["AntiV-SGN: a universal antiviral strategy to combat both RNA and DNA viruses by destroying their nucleic acids without sequence limitation."],"pmcid":["PMC9437879"],"pubmed_authors":["Tian K","Liu Y","Wang P","Qi Z","Zhu F","Xu S","Qiang H","Zhou G","Chi Y","Guo Q"],"additional_accession":[]},"is_claimable":false,"name":"AntiV-SGN: a universal antiviral strategy to combat both RNA and DNA viruses by destroying their nucleic acids without sequence limitation.","description":"Numerous viral outbreaks have threatened us throughout history. Here, we demonstrated a nucleic acid-based antiviral strategy named AntiV-SGN. Unlike those CRISPR-mediated methods, AntiV-SGN has advantages of no targets' sequence limitation, such as protospacer adjacent motif (PAM) or protospacer flanking sequence (PFS), being universal for both DNA and RNA viruses. AntiV-SGN was composed of a FEN1 protein and specific hpDNAs targeting viruses' nucleic acid. Its antiviral ability was tested on SARS-CoV-2 and HBV respectively. Reporter assays in human cells first illustrated the feasibility of AntiV-SGN. Then, it was verified that AntiV-SGN destroyed about 50% of live RNAs of SARS-CoV-2 in Vero cells and 90% cccDNA of HBV in HepG2.2.15 cells. It was also able to remove viral DNA integrated ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-18T22:42:22.657Z","creation":"2025-04-07T10:29:38.501Z"},"accession":"S-EPMC9437879","cross_references":{"pubmed":["35611874"],"doi":["10.1111/1751-7915.14076"]}}